Pliant Therapeutics, Inc. (PLRX): Revenue
$0
Year ended 2025-12-31
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | n/a | 2026-03-11, From 2025-01-01 |
| 2024-12-31 | $0 | -100.0% | 2026-03-11, From 2024-01-01 |
| 2023-12-31 | $1.58M | -83.7% | 2025-03-03, From 2023-01-01 |
| 2022-12-31 | $9.69M | +27.9% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $7.57M | -81.9% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $41.82M | -26.7% | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $57.05M | n/a | 2022-03-01, From 2019-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Pliant Therapeutics, Inc. (PLRX) | 2025-12-31 | $0 | n/a |
| Abbott Laboratories (ABT) | 2025-12-31 | $44.33B | +5.7% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $48.19B | -0.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $3.02M | +71.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $65.18B | +44.7% |
| Pfizer Inc (PFE) | 2025-12-31 | $62.58B | -1.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $94.19B | +6.0% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $480.14M | +5.7% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $65.01B | +1.3% |
Compare PLRX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗